Search

Your search keyword '"Avcin, Tadej"' showing total 460 results

Search Constraints

Start Over You searched for: Author "Avcin, Tadej" Remove constraint Author: "Avcin, Tadej"
460 results on '"Avcin, Tadej"'

Search Results

1. Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis

3. The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

7. The HyperPed-COVID international registry: Impact of age of onset, disease presentation and geographical distribution on the final outcome of MIS-C

9. Autoantibodies and Kidney Diseases

10. The Role of Complement in Kidney Disease: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

11. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study

12. Multisystem inflammatory syndrome in children: A review.

13. Extraintestinal Manifestations of Inflammatory Bowel Disease

14. The outcomes of children born to mothers with autoimmune rheumatic diseases

15. Differences Sustained Between Diffuse and Limited Forms of Juvenile Systemic Sclerosis in an Expanded International Cohort

16. The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET

17. Publisher Correction: The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET

19. Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria

20. Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases

23. 2023 ACR/EULAR antiphospholipid syndrome classification criteria

24. Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome

26. Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis.

30. Points to consider: EULAR–UEMS standards for the training of European rheumatologists

31. Application and performance of disease activity indices proposed for patients with systemic sclerosis in an international cohort of patients with juvenile systemic sclerosis

32. OA39 Development of a Childhood Lupus Low Disease Activity State definition: recommendations from the International Childhood Lupus Treat-to-Target Task Force

33. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

34. Application and performance of disease activity indices proposed for patients with systemic sclerosis in an international cohort of patients with juvenile systemic sclerosis

35. Gender differences in juvenile systemic sclerosis patients : Results from the international juvenile scleroderma inception cohort

36. Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus:PReS-endorsed overarching principles and points-to-consider from an international task force

37. Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases

38. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial

39. Perforin and Human Diseases

40. The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.

41. Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task force

43. Gender differences in juvenile systemic sclerosis patients: Results from the international juvenile scleroderma inception cohort

44. Care of patients with inborn errors of immunity in thirty J Project countries between 2004 and 2021

45. Antiphospholipid Antibody Syndrome

46. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative

47. Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to- consider from an international task force.

48. Gender equity in academic rheumatology, current status and potential for improvement: a cross-sectional study to inform an EULAR task force

49. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study

50. Underdetection of Interstitial Lung Disease in Juvenile Systemic Sclerosis

Catalog

Books, media, physical & digital resources